pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Zinc fingers. billion in funding.
Pharmaceutical Technology
MAY 24, 2023
The ability to modify or introduce genetic material in human cells in such a precise and patient-centered manner clearly constitutes a breakthrough in personalized medicine. CGT drugs fall into two major categories: autologous and allogeneic. What are the general differences in the supply chain of CGT vs. traditional clinical trials?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JANUARY 31, 2021
I always have pointed instances in which pharma puts Wall Street first and patients second. Here are some of her key points from the report: 1ne: In just 10 years, the number of large, international pharmaceutical companies decreased six-fold,from60 to only 10. In pharma R&D returns have declined to 1.8 percent from 2018.
XTalks
DECEMBER 20, 2023
In addition to Vertex and CRISPR Therapeutics, the latter co-founded by Emmanuelle Charpentier, one of the co-discoverers of CRISPR along with Jennifer Doudna, there are a host of other companies actively working on developing CRISPR-based treatments. Regulatory bodies are also taking note of the applications of AI in drug development.
Pharmaceutical Technology
APRIL 12, 2023
In February, Massachusetts-based Charles River Laboratories, the second-largest importer of nonhuman primates into the US, was served a subpoena by the US Department of Justice regarding the company’s import of wild long-tailed macaques from Cambodia. This was part of an investigation into an international primate smuggling ring.
Drug Discovery World
SEPTEMBER 28, 2022
Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. According to Hampleton Patners’ latest Healthtech M&A market report2, digital health companies raised a total of $57.2
Drug Discovery World
NOVEMBER 15, 2022
Developed with the idea of engineering an enzyme called terminal deoxynucleotidyl transferase (TdT), a type of DNA polymerase, these enzymatic DNA synthesis methods are now the focus of dozens of companies. Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .
Expert insights. Personalized for you.
145 
Let's personalize your content